Date: 2017-06-08
Type of information: Grant
Company: VBL Therapeutics (Israel)
Investors: Israel Innovation Authority (Israel) formerly known as the Office of the Chief Scientist (OCS)
Amount: $2.5 Million
Funding type: grant
Planned used:
- The funds will support the development of ofranergene obadenovec (VB-111), a targeted anti-cancer gene-therapy agent currently in development for recurrent glioblastoma, platinum-resistant ovarian cancer and other solid tumors.
Others:
- • On June 8, 2017, VBL Therapeutics announced that it has been awarded a grant of 8.75 million New Israeli Shekels (approximately $2.5 million) by the Israel Innovation Authority. The Israel Innovation Authority, formerly known as the Office of the Chief Scientist, which is responsible for the country’s innovation policy, is an independent and impartial public entity that operates for the benefit of the Israeli innovation ecosystem and the country’s economy as a whole.
Therapeutic area: Cancer - Oncology
Is general: Yes
